Newborn screening is the practice of testing newborn for certain disorders such as phenylketonuria (PKU), cystic fibrosis, sickle cell disease, critical congenital heart disease, hearing loss, and others. This testing is typically performed before the baby leaves the hospital. Early detection and treatment can help prevent intellectual and physical disabilities and life-threatening illnesses in newborn.
The newborn screening market growth is driven by several factors such as rising neonatal population base, increase in number of cases of congenital diseases in newborns. However, lack of improved healthcare infrastructure and trained professionals, and socioeconomic barriers are some of the major factors restraining the growth of the global newborn screening market.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
